TargetBeta
XPO1
exportin 1 · also CRM1, CRM-1, emb · Exportins
2 programs in company-led studies act on XPO1, from 2 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| selinexorrule | Karyopharm Therapeutics | phase 3 | 4012 running | – | NCIt |
| TQB3107 | Sino Biopharmaceutical | phase 1 | 11 running | – | the company's pipeline |
Conditions their studies are in
- Endometrial Neoplasms, 1 program
- Glioblastoma, 1 program
- Lymphoma, Large B-Cell, Diffuse, 1 program
- Multiple Myeloma, 1 program
- Primary Myelofibrosis, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026selinexor · Karyopharm Therapeutics · phase 3 · NCT04442022
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.